Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Healius Limited ( (AU:HLS) ) has shared an update.
Healius Limited has disclosed a change in the shareholding of director Steven Rubic, who increased his direct holding in the company through on-market trades. Rubic acquired 130,000 fully paid ordinary shares at an average price of $0.595 per share, lifting his direct ownership from 30,000 to 160,000 shares, a move that may be read by investors as a signal of confidence in the company’s prospects and alignment with shareholder interests.
The most recent analyst rating on (AU:HLS) stock is a Sell with a A$0.64 price target. To see the full list of analyst forecasts on Healius Limited stock, see the AU:HLS Stock Forecast page.
More about Healius Limited
Healius Limited is an Australian healthcare company operating primarily in pathology and diagnostic imaging services. The group provides medical testing and related health services across Australia, serving hospitals, clinicians, and patients in both metropolitan and regional markets.
Average Trading Volume: 2,788,552
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$446.6M
For an in-depth examination of HLS stock, go to TipRanks’ Overview page.